NCT05282030 - Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions

Renal Impairment

Interventions

DRUG

tolebrutinib

Pharmaceutical form: Film-coated tablets Route of administration: oral

Trial Locations (4)

Investigational Site Number : 2760001, Kiel

Clinical Pharmacology of Miami Site Number : 8400002, Miami

Volunteer Research Group-NOCCR Site Number : 8400003, Knoxville

Nucleus Network Site Number : 8400001, Saint Paul